Together, these converging alterations amplify TGF-β signaling activity and are strongly associated with poor clinical outcomes, reflecting a functionally significant reprogramming of the tumor signaling architecture [28,29,30,31]. This evidence concerns the gene TGFB1 and neoplasm.